FDA Push for TRF Therapies Will 'Disrupt Pain Market'
FDA’s push for abuse-resistant opioid formulations will disrupt the pain market, say analysts Frost & Sullivan. The opioid market is currently dominated by non-tamper resistant formulations (TRFs),...
View ArticleBRIC Opportunities 2014
While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for...
View ArticleGlobal Biosimilars Market to Soar to $24 Billion by 2019
Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market The market is expected to soar from $1.2 billion of 2013 to $24...
View ArticleRise in IPOs Eases Pharma's Investment Woes
Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment...
View ArticleClik here to view.
Indonesia “Most Promising” Emerging Market in 2015
Indonesia is expected to be the most promising market for pharma next year, thanks to its new healthcare insurance scheme Jaminan Kesehatan Nasional (JKN), according to Reenita Das, partner and senior...
View Article